Overview

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating patients with refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, or non-Hodgkin's lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

MedImmune LLC

Treatments:

Antibodies
Immunoconjugates
Immunotoxins